GlaxoSmithKline has announced an update on the discontinuation of Tanzeum (albiglutide) 30mg and 50mg injections, a treatment for type 2 diabetes.

The initial decision to discontinue Tanzeum was announced in August 2017 due to limited prescribing of the drug and not because of safety concerns. At the time, the supply of Tanzeum was expected to be depleted by July 2018 but the Company is now reporting the product will no longer be available as of May 2018.

Healthcare providers are being informed in advance to ensure sufficient time to transition existing patients taking Tanzeum to an alternative therapy.

Continue Reading

Tanzeum, a glucagon-like peptide-1 (GLP-1) receptor agonist, is indicated as an adjunct to diet and exercise, to improve glycemic control in adults with type 2 diabetes. It was approved by the Food and Drug Administration (FDA) in 2014. 

Related Articles


GlaxoSmithKline. Accessed January 31, 2018.

This article originally appeared on MPR